Is Sol-Gel Technologies Ltd. (NASDAQ:SLGL) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Sol-Gel Technologies Ltd. at current levels.
A 10x year already happened. The next leg depends on Gorlin Syndrome Phase 3 readout and Galderma royalty ramp turning a $243M dermatology micro-cap into something the orphan disease buyers can't ignore.
Where SLGL is headed
By the back half of 2027, Sol-Gel looks nothing like the sleepy royalty stub it traded as for years. SGT-610 (patidegib topical gel) is the only Phase 3 asset targeting Gorlin Syndrome, a rare genetic condition where patients develop hundreds of basal cell carcinomas over a lifetime. The current standard of care is repeated surgery. If the Phase 3 hits, Sol-Gel owns the first approved therapy in a population the company estimates at roughly 10,000 diagnosed patients in the US, with orphan drug exclusivity, pediatric extension potential, and pricing power that comparable rare derm assets (Krystal's Vyjuvek, Mindera-adjacent work) have already proven the market will pay for. A $300K-$400K annual price point against even a 2,000-patient addressable launch year gets you to $600M-$800M peak US sales with high gross margins because this is a topical, not a biologic.
Read the full Compass Direction on SLGL
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $76.73).
See the full SLGL analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Sol-Gel Technologies Ltd. (NASDAQ:SLGL) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Sol-Gel Technologies Ltd. at current levels. A 10x year already happened. The next leg depends on Gorlin Syndrome Phase 3 readout and Galderma royalty ramp turning a $243M dermatology micro-cap into something the orphan disease buyers can't ignore.
What is SLGL's Compass Score?
Sol-Gel Technologies Ltd. scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for SLGL?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the SLGL page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.